Tekla Capital Management LLC Puma Biotechnology, Inc. Transaction History

Tekla Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$9.5 - $11.14 $677,730 - $794,727	-71,340 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$20.77 - $42.37 $249,240 - $508,439	-12,000 Reduced 14.4%	71,340 $2.77 Million
Q2 2018 Aug 13, 2018	BUY	$48.3 - $68.25 $1.32 Million - $1.87 Million	27,355 Added 48.86%	83,340 $4.93 Million
Q1 2018 May 14, 2018	BUY	$59.7 - $99.25 $453,302 - $753,605	7,593 Added 15.69%	55,985 $3.81 Million
Q4 2017 Feb 14, 2018	SELL	$93.85 - $132.45 $5.36 Million - $7.56 Million	-57,103 Reduced 54.13%	48,392 $4.78 Million
Q3 2017 Nov 13, 2017	SELL	$72.0 - $119.75 $6.99 Million - $11.6 Million	-97,042 Reduced 47.91%	105,495 $12.6 Million
Q2 2017 Aug 14, 2017	BUY	N/A	202,537	202,537 $17.7 Million

30.5M

73.5K

18.5K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $118M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.